Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of “Buy” by Analysts

Shares of Solid Biosciences Inc. (NASDAQ:SLDB) have received a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $15.67.

SLDB has been the subject of several research analyst reports. Truist Financial assumed coverage on Solid Biosciences in a report on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price objective for the company. HC Wainwright lifted their price target on shares of Solid Biosciences from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Chardan Capital reissued a “buy” rating and set a $16.00 price objective on shares of Solid Biosciences in a report on Friday, March 7th. Wedbush started coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an “outperform” rating and a $16.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of Solid Biosciences from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, March 13th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Solid Biosciences during the 4th quarter valued at $34,000. The Manufacturers Life Insurance Company purchased a new position in Solid Biosciences during the third quarter valued at $71,000. Corton Capital Inc. bought a new stake in Solid Biosciences during the fourth quarter valued at about $41,000. Invesco Ltd. bought a new position in shares of Solid Biosciences in the fourth quarter worth about $49,000. Finally, Sei Investments Co. purchased a new position in shares of Solid Biosciences during the 4th quarter valued at about $52,000. 81.46% of the stock is currently owned by institutional investors.

Solid Biosciences Trading Up 1.1 %

Solid Biosciences stock opened at $2.70 on Monday. Solid Biosciences has a 12 month low of $2.48 and a 12 month high of $10.99. The stock has a fifty day simple moving average of $4.38 and a two-hundred day simple moving average of $4.81. The firm has a market cap of $209.23 million, a price-to-earnings ratio of -0.89 and a beta of 2.07.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.